Drug
Calderasib
Calderasib: highest development phase Phase 3, developed by Merck. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Calderasib NCT07190248 | Phase 3 | Non-small Cell Lung Cancer |
| Calderasib NCT07554339 | Phase 3 | Non-small Cell Lung Cancer |
| Calderasib NCT06345729 | Phase 3 | Non-small Cell Lung Cancer |
| Calderasib NCT07431827 | Phase 3 | Non-small Cell Lung Cancer |
Latest
No recent events.
Follow Calderasib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.